Institutional members access full text with Ovid®

BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression

Viikki, Merja L.a,c; Järventausta, Kaijad; Leinonen, Esaa,d; Huuhka, Marttid; Mononen, Ninab; Lehtimäki, Terhob; Kampman, Ollia,e

doi: 10.1097/YPG.0b013e328360c894
Brief Reports

The aim of the present study was to test for a possible association between two brain-derived neurotrophic factor (BDNF) polymorphisms (rs11030101 and rs61888800) and the efficacy of electroconvulsive therapy (ECT) [change in Montgomery–Åsberg Depression Rating Scale (MADRS)]. So far, there are no studies investigating an association between these polymorphisms and the efficacy of ECT. The patient sample included 119 patients with treatment-resistant major depressive disorder who were treated with ECT. BDNF polymorphism rs11030101, but not rs61888800, was associated with a change in the MADRS score. Patients with the TA genotype of rs11030101 were less likely to benefit from ECT compared with patients with the TT genotype (P=0.041). The finding suggests an association between BDNF polymorphism rs11030101 and the efficacy of ECT. Further studies with larger samples will be required to confirm this finding.

Departments of aPsychiatry

bClinical Chemistry, Medical School, University of Tampere

cDepartment of Psychiatry, Tampere Mental Health Centre

dDepartment of Psychiatry, Tampere University Hospital, Tampere

eDepartment of Psychiatry, Seinäjoki Hospital District, Seinäjoki, Finland

Correspondence to Merja L. Viikki MD, PhD, Medical School, University of Tampere, 33014 Tampere, Finland Tel: +358 50 3396646; fax: +358 3 35516164; e-mail: merja.viikki@gmail.com

Received June 2, 2012

Accepted November 15, 2012

© 2013 Lippincott Williams & Wilkins, Inc.